KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Other financing activities (2017 - 2021)

Historic Other financing activities for Twist Bioscience (TWST) over the last 4 years, with Q4 2021 value amounting to -$2.6 million.

  • Twist Bioscience's Other financing activities fell 614.11% to -$2.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$11.0 million, marking a year-over-year decrease of 17335.32%. This contributed to the annual value of -$10.8 million for FY2021, which is 34812.06% down from last year.
  • Twist Bioscience's Other financing activities amounted to -$2.6 million in Q4 2021, which was down 614.11% from -$2.6 million recorded in Q3 2021.
  • Over the past 5 years, Twist Bioscience's Other financing activities peaked at $1.4 million during Q1 2018, and registered a low of -$3.3 million during Q1 2021.
  • Over the past 4 years, Twist Bioscience's median Other financing activities value was -$611500.0 (recorded in 2020), while the average stood at -$1.1 million.
  • The largest annual percentage gain for Twist Bioscience's Other financing activities in the last 5 years was 614.11% (2021), contrasted with its biggest fall of 75666.67% (2021).
  • Over the past 4 years, Twist Bioscience's Other financing activities (Quarter) stood at $470000.0 in 2017, then fell by 7.66% to $434000.0 in 2018, then tumbled by 655.3% to -$2.4 million in 2020, then fell by 6.14% to -$2.6 million in 2021.
  • Its Other financing activities stands at -$2.6 million for Q4 2021, versus -$2.6 million for Q3 2021 and -$2.5 million for Q2 2021.